A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Researchers evaluated the addition of the AKT inhibitor ipatasertib to mFOLFOX6 for patients with gastric cancer.
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: Results from the randomized prospective phase III FFCD-0307 trial
New research shared in MD Linx looks at prognostic factors in patients with advanced gastric cancer treated with second-line chemotherapy.
Women more prone to selected oesophagogastric cancer chemotherapy side-effects
New research presented at ESMO investigates whether men and women should be treated differently in cancer care, finding women are more prone... Read More
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Research published in the American Society of Clinical Oncology shows nivolumab and nivolumab plus ipilimumab has durable response and encouraging long-term overall survivial... Read More
Adjuvant Chemotherapy or Adjuvant Chemoradiotherapy for Gastric Cancer?—A West Cancer Center Perspective
“If you gave everybody neoadjuvant chemotherapy, is there an added benefit for chemoradiation after surgery?” Watch researchers from West Cancer Center explain... Read More
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer
A global Phase 3 trial is comparing the efficacy and safety of pamiparib to placebo as maintenance therapy in advanced gastric cancer... Read More
Timing of postoperative chemotherapy in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer
A study examines the timing of postoperative chemo on survival of gastric cancer patients who underwent perioperative chemotherapy and gastrectomy.
Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1
A new study shows possible clinical benefits of intraperitoneal paclitaxel for gastric cancer. Published in the Journal of Clinical Oncology, An American... Read More
Phase 3 study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013)
Presented at the American Society of Clinical Oncology annual conference, researchers from Japan found doublet chemo with S-1 and cisplatin (CS) first-line... Read More
Added radiotherapy does not improve gastric cancer survival
New findings from an international clinical trial: postoperative chemoradiotherapy after gastric cancer surgery does not improve overall survival, compared with postoperative chemotherapy... Read More
